Setting new standards in information exchange for the pharmaceutical and biotech industry
Congratulations to Rational Combinations 360° Speaker Zachary Roberts and His Team at Kite Pharma for the FDA Approval of the 2nd Gene-Altering Treatment for Cancer
October 19, 2017
Congratulations to Rational Combinations 360° Speaker Zachary Roberts and his team at Kite Pharma for the FDA approval of Yescarta, a gene therapy for adults with aggressive forms of a blood cancer, non-Hodgkin’s lymphoma, who have not responded to or who have relapsed after at least two other kinds of treatment. This is the second cutting-edge CAR-T therapy to be approved in what The New York Times quotes “the radically new class of treatments that genetically reboot a patients own immune cells to kill cancer.”
“Today marks another milestone in the development of a whole new scientific paradigm for the treatment of serious diseases,” the FDA commissioner, Dr Scott Gottlieb, said in a statement. “In just several decades, gene therapy has gone from being a promising concept to a practical solution to deadly and largely untreatable forms of cancer.”
Kymriah, developed by Novartis, was the first CAR-T therapy to gain FDA approval this past August and is used to treat acute lymphoblastic lymphoma. Dr David Lebwohl, who heads the CAR-T Franchise Global Program at Novartis, will be sharing “Key Learnings from Kymriah – From Pivotal Trials to Launch” at Immuno-Oncology 360° (IO360°) February 7-9, 2018 in New York City.